Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of TDV in Healthy Adults
NCT03746015Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of dengue tetravalent vaccine (live, attenuated) in dengue fever, sponsored by Takeda. Started Dec 2018; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03746015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746015.